<DOC>
	<DOCNO>NCT01093690</DOCNO>
	<brief_summary>The objective study assess efficacy tolerability metoclopramide add standard antiemetic regimen prophylaxis cisplatin-induced emesis .</brief_summary>
	<brief_title>Ondansetron Plus Dexamethasone With Without Metoclopramide Antiemetic Prophylaxis After Receiving Cisplatin</brief_title>
	<detailed_description>Ondansetron plus dexamethasone standard emetic prophylactic agent highly emetogenic chemotherapy . Metoclopramide dopamine antagonist , may enhance efficacy ondansetron dexamethasone .</detailed_description>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Antiemetics</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>schedule receive first cycle cisplatin &gt; 50 mg/m^2 pathologically histologically confirm solid cancer 18 year old creatinine clearance 50 ml/min aminotransferase less 2 time upper normal limit pregnant woman patient episode vomit within 24 hour prior chemotherapy session gut obstruction brain metastasis abdominal pelvic irradiation history allergy study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>chemotherapy induce nausea vomiting , metoclopramide</keyword>
</DOC>